A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

BACKGROUND: Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory acute myeloid leukemia (R/R AML) is emerging. However, it is unknown how VEN-combined low intensity treatment compares to intensive chemotherapy (IC) in medically fit patients with R/R AML. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Silvia, Kwag, Daehun, Kim, Tong Yoon, Lee, Jong Hyuk, Lee, Joon yeop, Min, Gi June, Park, Sung Soo, Yahng, Seung-Ah, Jeon, Young-Woo, Shin, Seung-Hwan, Yoon, Jae-Ho, Lee, Sung-Eun, Cho, Byung Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong Wook, Kim, Hee-Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949776/
https://www.ncbi.nlm.nih.gov/pubmed/35340720
http://dx.doi.org/10.1177/20406207221081637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949776/
https://www.ncbi.nlm.nih.gov/pubmed/35340720
http://dx.doi.org/10.1177/20406207221081637

Ejemplares similares